The D-SOLVE Consortium brings together researchers with outstanding clinical, virological, immunological and bioinformatical expertise from Italy, Romania, Germany, France and Sweden to achive an individualized management of HDV. Clinical centers with an outstanding experience in translational research in Milan, Stockholm, Hannover and Bucharest will establish a cohort of 750 HDV patients that is the basis of an unbiased biomarker screening.

The D-SOLVE consortium hypothesize that comprehensive and unbiased screening of a large multicenter cohort of well-defined HDV-infected patients, followed by mechanistic studies to determine the functional role of distinct molecules will identify specific parameters and tools which can have an immediate impact to the management of patients with this most severe viral liver disease. Patient surveillance strategies and antiviral treatment approaches could be personalized which should reduce clinical and social disease burden and improve quality of life.

We established the D-SOLVE academy, a program that enables the exchange between D-Solve centers. We aim to gain experience in the treatment and diagnostics of hepatitis D and to strengthen knowledge transfer between scientists and students. The D-SOLVE academy is be open for scientists and physicians from other institutes and clinic hospitals (“train the trainer”). By this, the D-SOLVE spirit and expertise will be disseminated through Europe and the World.